Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: Acura®, Cetimax, Cetirizin ABECE, Cetirizin Actavis, Cetirizin Apofri, Cetirizin Bluefish, Cetirizin Generics, Cetirizin HEXAL, Cetirizin Mylan, Cetirizin Sandoz, Cetirizin STADA®, Cetirizine Teva, Vialerg, Zanlan, Zyrlex®

ATC code: R06AE07

Substances: cetirizine, cetirizine hydrochloride


Controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of cetirizine are lacking.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of cetirizine have been found.


No studies with a clinically relevant sex analysis regarding effects of cetirizine have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of cetirizine have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A prospective study of consecutive patients (85 men and boys, 163 women and girls) attending allergy care showed that acute urticaria was more common in women than in men (73 vs 27%) with a predominance of middle-aged women with a history of atopic eczema. The prevalence of acute urticaria was similar in boys and girls. The drugs of choice were cetirizine and levocetirizine in children while adults more often were treated with fexofenadine, cetirizine, levocetirizine, and systemic corticosteroids [1].

Updated: 2020-08-28

Date of litterature search: 2017-03-23


  1. Sánchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Demographic and clinical profiles in patients with acute urticaria. Allergol Immunopathol (Madr). 2015;43:409-15. PubMed
  2. Concise. Stockholm: eHälsomyndigheten. 2015 [cited 2017-03-02.] länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-03-23.] länk

Authors: Maria Enghag

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson